Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet ...
Putting tariffs on Denmark unless it cedes the island of Greenland could hurt access to a few key products, including popular ...
A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...
Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...
Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...
Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...
Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...
It’s not at all clear what a tariff would mean for Novo, which manufactures its medicines in facilities all over the world, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback